Robin Wright
Vermögen: 32 862 $ am 31.05.2026
Vermögen: 32 862 $ am 31.05.2026
Robin Wright currently works at Barinthus Biotherapeutics (UK) Ltd., as Chairman, Barinthus Biotherapeutics Plc, as Chairman from 2018, KDev Investments AB, as Director, and The Institute of Chartered Accountants in England & Wales, as Fellow.
Mr. Wright also formerly worked at Pharming Group NV, as Chief Financial Officer from 2015 to 2020, Orexo AB, as CFO & Head-Business Development from 2008 to 2011, and Karolinska Development AB (Private Equity), as Chief Financial Officer from 2011 to 2014.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.06.2026 | 48.256 ( 0,12 % ) | 32 862 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BARINTHUS BIOTHERAPEUTICS PLC | Vorsitzender | 01.10.2018 |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology Engages in research, sales, and development in the fields of medicine and owns and manages investments | Direktor/Vorstandsmitglied | - |
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Vorsitzender | - |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Corporate Officer/Principal | - |
| Unternehmen | Position | Ende |
|---|---|---|
| PHARMING GROUP N.V. | Finanzdirektor/CFO | 20.05.2020 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development seeks investment in companies located in the Nordic region, primarily in Swedish. The firm targets companies operating in the fields of health technology, health services, medical devices, technology services, life science. It provides financing for early stage capital requirements. It takes a seat on the board of directors. | Finanzdirektor/CFO | 28.02.2014 |
| OREXO AB | Finanzdirektor/CFO | 01.06.2011 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 8 |
|---|---|
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Commercial Services |
Pharming Group NV
Pharming Group NV Pharmaceuticals: MajorHealth Technology Develops and commercializes protein replacement therapies and precision medicines | Health Technology |
Orexo AB
Orexo AB Pharmaceuticals: MajorHealth Technology Manufactures and commercializes pharmaceutical products | Health Technology |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development seeks investment in companies located in the Nordic region, primarily in Swedish. The firm targets companies operating in the fields of health technology, health services, medical devices, technology services, life science. It provides financing for early stage capital requirements. It takes a seat on the board of directors. | Finance |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology Engages in research, sales, and development in the fields of medicine and owns and manages investments | Health Technology |
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
Vaccitech Plc
Vaccitech Plc Pharmaceuticals: MajorHealth Technology Discovers and develops immunotherapeutic products and vaccines for the treatment and prevention of infectious and cancer diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen